IntelGenx Technologies Corp., a drug delivery company, focuses on the development of novel oral immediate-release and controlled-release products for the pharmaceutical market. It offers RIZAPORT, an oral thin film formulation of rizatriptan benzoate for the treatment of acute migraines. The company's products under development comprise INT0001/2004, an anti-hypertension drug; INT0004/2006, an antidepressant; INT0007/2006 for the treatment of erectile dysfunction; INT0008/2008 for migraine; INT0010/2006 for the treatment of neuropathic pain and nausea in cancer patients; INT0027/2011 to treat opioid dependence; INT0036/2013 for schizophrenia; and INT0043/2015 to treat Alzheimer's disease. It is also developing INT0037/2013, INT0039/2013, INT0040/2014, INT0045/2018, INT0046/2018. The company has co-development and commercialization agreements with RedHill Biopharma Ltd., Par Pharmaceutical Companies, Inc., and Endo Ventures Ltd.; licensing, development, and supply agreement with Tilray, Inc., Gensco Pharma, and Chemo Group; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone514-331-7440
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesC$1.96 million
Profitability
Miscellaneous
Employees38
Next Earnings Date11/14/2019 (Estimated)
OptionableNot Optionable
IntelGenx Technologies (CVE:IGX) Frequently Asked Questions
What is IntelGenx Technologies' stock symbol?
IntelGenx Technologies trades on the Canadian Venture Exchange (CVE) under the ticker symbol "IGX."
How were IntelGenx Technologies' earnings last quarter?
IntelGenx Technologies Corp. (CVE:IGX) posted its quarterly earnings results on Thursday, August, 8th. The company reported ($0.04) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.03) by $0.01. The business earned $0.26 million during the quarter, compared to the consensus estimate of $1.21 million. View IntelGenx Technologies' Earnings History.
When is IntelGenx Technologies' next earnings date?
Has IntelGenx Technologies been receiving favorable news coverage?
News stories about IGX stock have been trending somewhat negative this week, according to InfoTrie. The research group identifies positive and negative media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. IntelGenx Technologies earned a daily sentiment score of -1.3 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for IntelGenx Technologies.
Who are some of IntelGenx Technologies' key competitors?
Some companies that are related to IntelGenx Technologies include Botanix Pharmaceuticals (BOT), Enochian Biosciences (ENOB), IMV (IMV), Neuren Pharmaceuticals (NEU), CorMedix (CRMD), CorMedix (CRMD), Bioventix (BVXP), Silence Therapeutics (SLN), Lineage Cell Therapeutics (LCTX), Cynata Therapeutics (CYP), Burcon NutraScience (BU), MediGene (MDG1), Arix Bioscience (ARIX), IMV (IMV) and Ampliphi Biosciences (APHB).
What other stocks do shareholders of IntelGenx Technologies own?
Who are IntelGenx Technologies' key executives?
IntelGenx Technologies' management team includes the folowing people:
- Dr. Horst G. Zerbe, Founder, Chairman, CEO & Chairman of Scientific Advisory Board (Age 72)
- Mr. Andre Godin C.A., CPA, CPA, CA, Exec. VP, Pres & CFO (Age 55)
- Dr. Dana Matzen, VP of Bus. & Corp. Devel. (Age 41)
- Ms. Nadine Paiement, Vice-Chair of Scientific Advisory Board and VP of R&D (Age 42)
- Ms. Ingrid Zerbe, Co-Founder & Corp. Sec. (Age 65)
How do I buy shares of IntelGenx Technologies?
Shares of IGX and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is IntelGenx Technologies' stock price today?
One share of IGX stock can currently be purchased for approximately C$0.72.
How big of a company is IntelGenx Technologies?
What is IntelGenx Technologies' official website?
How can I contact IntelGenx Technologies?
The company can be reached via phone at 514-331-7440.
MarketBeat Community Rating for IntelGenx Technologies (CVE IGX)
MarketBeat's community ratings are surveys of what our community members think about IntelGenx Technologies and other stocks. Vote "Outperform" if you believe IGX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IGX will underperform the S&P 500 over the long term. You may vote once every thirty days.
